Drug intelligence / Profile preview

TB581

Development stage: Preclinical
Lead developer: Twinpig Biolab
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

TB581 is a multi-target peptide-drug conjugate (PDC) developed by TwinPigBio using their proprietary TAMpep™ - ESCLink™ platform. It is designed to simultaneously target tumor-associated macrophages (TAMs) via active CD18 and Nectin-4-expressing tumor cells. The drug utilizes a TAMpep peptide to deliver a dKLA (proapoptotic peptide) payload directly to the tumor microenvironment. By targeting both the immunosuppressive TAMs and the cancer cells themselves, TB581 aims to overcome tumor resistance and enhance therapeutic efficacy. It is currently in the preclinical stage, having completed lead optimization.

Targets

PVRL4 (Nectin cell adhesion molecule 4)CD18 (Integrin beta-2)

Beyond the preview

Go deeper on TB581.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB581.

Explore the full profile